These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 21320060)

  • 1. Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neurodegenerative tauopathies.
    Ballatore C; Brunden KR; Trojanowski JQ; Lee VM; Smith AB; Huryn DM
    Curr Top Med Chem; 2011; 11(3):317-30. PubMed ID: 21320060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microtubule stabilizing agents as potential treatment for Alzheimer's disease and related neurodegenerative tauopathies.
    Ballatore C; Brunden KR; Huryn DM; Trojanowski JQ; Lee VM; Smith AB
    J Med Chem; 2012 Nov; 55(21):8979-96. PubMed ID: 23020671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy.
    Brunden KR; Zhang B; Carroll J; Yao Y; Potuzak JS; Hogan AM; Iba M; James MJ; Xie SX; Ballatore C; Smith AB; Lee VM; Trojanowski JQ
    J Neurosci; 2010 Oct; 30(41):13861-6. PubMed ID: 20943926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.
    Zhang B; Carroll J; Trojanowski JQ; Yao Y; Iba M; Potuzak JS; Hogan AM; Xie SX; Ballatore C; Smith AB; Lee VM; Brunden KR
    J Neurosci; 2012 Mar; 32(11):3601-11. PubMed ID: 22423084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A brain-penetrant triazolopyrimidine enhances microtubule-stability, reduces axonal dysfunction and decreases tau pathology in a mouse tauopathy model.
    Zhang B; Yao Y; Cornec AS; Oukoloff K; James MJ; Koivula P; Trojanowski JQ; Smith AB; Lee VM; Ballatore C; Brunden KR
    Mol Neurodegener; 2018 Nov; 13(1):59. PubMed ID: 30404654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of Brain-Penetrant Pyrimidine-Containing Molecules with Differential Microtubule-Stabilizing Activities Developed as Potential Therapeutic Agents for Alzheimer's Disease and Related Tauopathies.
    Kovalevich J; Cornec AS; Yao Y; James M; Crowe A; Lee VM; Trojanowski JQ; Smith AB; Ballatore C; Brunden KR
    J Pharmacol Exp Ther; 2016 May; 357(2):432-50. PubMed ID: 26980057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.
    Brunden KR; Ballatore C; Lee VM; Smith AB; Trojanowski JQ
    Biochem Soc Trans; 2012 Aug; 40(4):661-6. PubMed ID: 22817712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies.
    Brunden KR; Yao Y; Potuzak JS; Ferrer NI; Ballatore C; James MJ; Hogan AM; Trojanowski JQ; Smith AB; Lee VM
    Pharmacol Res; 2011 Apr; 63(4):341-51. PubMed ID: 21163349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The protein-protein interactions as a target in medicinal chemistry and drug discovery.
    Mustata G
    Curr Top Med Chem; 2011; 11(3):247. PubMed ID: 21320055
    [No Abstract]   [Full Text] [Related]  

  • 10. Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease.
    Brunden KR; Trojanowski JQ; Smith AB; Lee VM; Ballatore C
    Bioorg Med Chem; 2014 Sep; 22(18):5040-9. PubMed ID: 24433963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.
    Barten DM; Fanara P; Andorfer C; Hoque N; Wong PY; Husted KH; Cadelina GW; Decarr LB; Yang L; Liu V; Fessler C; Protassio J; Riff T; Turner H; Janus CG; Sankaranarayanan S; Polson C; Meredith JE; Gray G; Hanna A; Olson RE; Kim SH; Vite GD; Lee FY; Albright CF
    J Neurosci; 2012 May; 32(21):7137-45. PubMed ID: 22623658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau and Axonal Transport Misregulation in Tauopathies.
    Combs B; Mueller RL; Morfini G; Brady ST; Kanaan NM
    Adv Exp Med Biol; 2019; 1184():81-95. PubMed ID: 32096030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies.
    Jangampalli Adi P; Reddy PH
    Biochim Biophys Acta Mol Basis Dis; 2021 Aug; 1867(8):166162. PubMed ID: 33940164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.
    Khanna MR; Kovalevich J; Lee VM; Trojanowski JQ; Brunden KR
    Alzheimers Dement; 2016 Oct; 12(10):1051-1065. PubMed ID: 27751442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies.
    Venkatramani A; Panda D
    Int J Biol Macromol; 2019 Jul; 133():473-483. PubMed ID: 31004638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Small Molecule Inhibitors of Tau Aggregation by Targeting Monomeric Tau As a Potential Therapeutic Approach for Tauopathies.
    Pickhardt M; Neumann T; Schwizer D; Callaway K; Vendruscolo M; Schenk D; St George-Hyslop P; Mandelkow EM; Dobson CM; McConlogue L; Mandelkow E; Tóth G
    Curr Alzheimer Res; 2015; 12(9):814-28. PubMed ID: 26510979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tau phosphorylation and aggregation as a therapeutic target in tauopathies.
    Badiola N; Suárez-Calvet M; Lleó A
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):727-40. PubMed ID: 20942789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
    Brunden KR; Trojanowski JQ; Lee VM
    Nat Rev Drug Discov; 2009 Oct; 8(10):783-93. PubMed ID: 19794442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration.
    Durairajan SSK; Selvarasu K; Bera MR; Rajaram K; Iyaswamy A; Li M
    Curr Mol Pharmacol; 2022; 15(2):361-379. PubMed ID: 34488602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies.
    Gallo JM; Noble W; Martin TR
    Cell Mol Life Sci; 2007 Jul; 64(13):1701-14. PubMed ID: 17453144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.